11月10日 - ** 基因治疗公司MeiraGTx Holdings MGTX.O股价盘前上涨11.5%至9.44美元
** 公司宣布与礼来LLY.N开展战略合作，开发眼科疾病的基因疗法
** 礼来获得了MeiraGTx针对LCA4（一种由AIPL1基因缺陷引起的罕见遗传性眼病）的基因治疗项目的全球独家代理权
** MeiraGTx将获得7500万美元的预付款，并有资格获得总额超过4亿美元的里程碑付款
** 截至上次收盘，该公司股价年累计上涨39.1%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.